| Code | CSB-RA003995MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to IM-101, designed for research involving complement component 5 (C5). C5 is a critical protein in the complement cascade, an essential part of the innate immune system that aids in pathogen clearance and inflammatory responses. Upon activation, C5 is cleaved into C5a, a potent anaphylatoxin that recruits inflammatory cells, and C5b, which initiates formation of the membrane attack complex (MAC). Dysregulated C5 activity is implicated in numerous complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis, and various autoimmune and inflammatory conditions.
IM-101 is a reference therapeutic antibody that targets C5, preventing its cleavage and subsequent downstream complement activation. This biosimilar antibody serves as a valuable research tool for investigating complement-mediated pathology, exploring C5 inhibition mechanisms, and studying immune regulation in disease models. It enables researchers to examine the role of C5 in inflammatory processes, evaluate potential therapeutic strategies, and advance understanding of complement biology in health and disease.
There are currently no reviews for this product.